Physician profile
Frederick D Hall
NPI 1215900949
$7,710.01
in general payments reported to CMS, 2019-2025
30 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $509 · 2021: $819 · 2022: $1,004 · 2023: $1,023 · 2024: $2,293 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359 · Travel and Lodging: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.62 |
| Travel and Lodging | $1,131.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,193.53 | 2019-2025 | Clareon, Argos, Centurion |
| Abbvie INC. | $622.32 | 2022-2025 | |
| Allergan, INC. | $483.60 | 2019-2022 | |
| Biotissue Holdings INC. | $400.72 | 2019-2025 | |
| Glaukos Corporation | $351.24 | 2020-2025 | Photrexa Viscous and Photrexa, Istent Infinite Trabecular Micro-Bypass System Model Is3, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $349.03 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $346.20 | 2019-2022 | |
| Oyster Point Pharma, INC. | $269.92 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Ivantis, INC | $227.83 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $220.64 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $164.95 | 2019-2023 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $157.31 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $153.28 | 2022-2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.78 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $104.81 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $91.44 | 2025 | Oxervate |
| Lensar, INC. | $66.05 | 2025 | Lensar Laser System |
| Carl Zeiss Meditec USA, INC. | $60.84 | 2021 | |
| Optos, INC. | $59.02 | 2022 | |
| Eyevance Pharmaceuticals LLC | $44.76 | 2020-2022 | |
| Harrow Eye, LLC | $44.63 | 2024-2025 | Vevye |
| Omeros Corporation | $32.50 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.98 | 2021 | |
| Sight Sciences, INC. | $19.91 | 2020 | |
| Shire North American Group INC | $19.80 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.77 | 2019 | |
| Eyepoint US, INC. | $17.52 | 2019 | |
| Organogenesis INC. | $15.49 | 2024 | Apligraf |
| Ocular Therapeutix, INC. | $14.55 | 2022 | |
| Coopervision INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.